Lisata Therapeutics, Inc. (LSTA)
NCM · Healthcare · Biotechnology
$1.63
-0.61%
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
Market Cap
$14.7M
Shares Outstanding
9.0M
P/S (TTM)
147x
Exchange
NCM
Currency
USD
About Lisata Therapeutics, Inc.
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with range of anti-cancer regimens. The company was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 0.00 | 100K | 0.00 | 0.00 |
| Operating Income | (4.4M) | (3.1M) | (4.9M) | (4.0M) |
| Net Income | (4.2M) | (3.0M) | (4.5M) | (2.9M) |
| Diluted EPS | $-0.49 | N/A | $-0.50 | $-0.32 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 1.0M | 170K |
| Operating Income | (57.6M) | (25.7M) | (22.4M) | (18.2M) |
| Net Income | (54.2M) | (20.8M) | (20.0M) | (16.6M) |
| Diluted EPS | $-10.47 | $-2.58 | $-2.40 | $-1.91 |